Table 3

Efficacy analysis according to various factors in the CAP cohort

FactornObjective response rateProgression-free survivalOverall survival
% (95% CI)P value*Median (95% CI), monthsHR (95% CI)†P value†Median (95% CI), monthsHR (95% CI)†P value†
PD-L1 TPS
 ≥50%2317.4 (4.95 to 38.78)0.53 1.94 (1.41 to 4.60)1.225 (0.685 to 2.190)0.4910.41 (5.85 to 13.93)1.997 (0.955 to 4.178)0.07
 1%–49%417.3 (1.54 to 19.92)0.047§3.75 (2.07 to 6.44)0.692 (0.410 to 1.170)0.179.72 (6.80 to 12.39)1.824 (0.975 to 3.412)0.06
 <1%3225.8 (11.86 to 44.61)3.88 (2.99 to 5.36)1.00 (reference)14.72 (9.49 to NR)1.00 (reference)
Duration of PD-1 inhibitor treatment
 ≥12 weeks8320.0 (11.89 to 30.44)0.593.94 (2.53 to 4.63)0.773 (0.580 to 1.028)0.0811.79 (8.02 to 13.60)0.753 (0.534 to 1.062)0.11
 <12 weeks16016.9 (11.43 to 23.59)2.76 (2.27 to 3.88)1.00 (reference)9.00 (7.33 to 10.58)1.00 (reference)
Objective response for PD-1 inhibitor
 CR or PR3523.5 (10.75 to 41.17)0.343.29 (1.84 to 5.52)0.909 (0.605 to 1.363)0.6410.18 (7.20 to NR)0.882 (0.550 to 1.414)0.60
 SD or PD20316.9 (12.01 to 22.83)3.22 (2.53 to 4.04)1.00 (reference)9.59 (8.02 to 11.66)1.00 (reference)
Interval from last dose of PD-1 inhibitor to start of subsequent chemotherapy
 ≥4 weeks12418.7 (12.24 to 26.72)0.872.96 (2.10 to 3.91)1.023 (0.780 to 1.341)0.878.54 (7.29 to 10.58)1.140 (0.831 to 1.563)0.42
 <4 weeks11917.1 (10.77 to 25.16)3.75 (2.53 to 4.37)1.00 (reference)10.78 (7.85 to 12.65)1.00 (reference)
EGFR or ALK alteration status
 Positive3221.9 (9.28 to 39.97)0.624.60 (2.50 to 6.83)0.879 (0.582 to 1.328)0.5413.11 (9.59 to NR)0.595 (0.354 to 0.999)0.0496
 Negative or unknown21117.3 (12.43 to 23.15)2.96 (2.40 to 3.88)1.00 (reference)8.67 (7.49 to 10.78)1.00 (reference)
History of curative radiotherapy
 Yes1718.8 (4.05 to 45.65)>0.992.40 (1.74 to 6.90)1.030 (0.586 to 1.809)0.9213.47 (6.34 to NR)0.656 (0.322 to 1.337)0.25
 No22617.9 (13.07 to 23.51)3.29 (2.53 to 3.98)1.00 (reference)9.10 (7.89 to 10.84)1.00 (reference)
  • *P values were determined with Fisher’s exact test.

  • †HRs with 95% CI and p values were calculated with the Cox proportional hazards regression model.

  • ‡P value is for comparison between ≥50% and<1%.

  • §P value is for comparison between 1%–49% and <1%.

  • CAP, chemotherapy after PD-1 inhibitor treatment; CR, complete response; NR, not reached; PD, progressive disease; PR, partial response; SD, stable disease; TPS, tumor proportion score.